








Karin Haar, Sandra Dudareva-Vizule,  
Hilmar Wisplinghoff, Fabian Wisplinghoff,  
Andrea Sailer, Klaus Jansen, Birgit Henrich,  
and Ulrich Marcus
To determine prevalence of lymphogranuloma vene-
reum	among	men	who	have	sex	with	men	 in	Germany,	
we conducted a multicenter study during 2009–2010 and 
found high rates of rectal and pharyngeal infection in men 
positive for the causative agent, Chlamydia trachomatis. 
Many infections were asymptomatic. An adjusted C. 
trachomatis	screening	policy	is	justified	in	Germany.
Lymphogranuloma venereum (LGV) is a sexually trans-mitted disease caused by infection with Chlamydia 
trachomatis bacteria, genotypes L1–L3. An outbreak of 
proctitis cases caused by C. trachomatis genotype L2 in 
men who have sex with men (MSM) became apparent in 
the Netherlands in 2003; subsequently, awareness of this 
disease increased throughout Europe (1).
In the United Kingdom and the United States, guide-
lines recommend rectal C. trachomatis screening for MSM 
(2). In Germany, no screening recommendations for as-
ymptomatic MSM exist, and nationally, no C. trachomatis 
prevalence data are available. We investigated the preva-
lence of pharyngeal and rectal C. trachomatis infection and 
LGV among MSM in Germany.
The Study
We conducted a prospective, multicenter study dur-
ing December 1, 2009–December 31, 2010, by recruiting a 
convenience sample of MSM at sentinel sites for sexually 
transmitted infections throughout Germany. Inclusion crite-
ria were being MSM, having >1 male sexual partner within 
the previous 6 months, and agreeing to provide a rectal and/
or pharyngeal swab specimen. To measure factors associ-
ated with HIV status, enrollment at sites providing HIV care 
was enhanced.
Rectal and pharyngeal specimens were collected ac-
cording to standardized protocols; urine testing or collec-
tion of urethral swabs was optional. All specimens were 
sent to a privately owned laboratory (Laboratoriumsmed-
izin Koeln,  Cologne, Germany), and tested for C. tracho-
matis by using the APTIMA Combo 2 Assay (GenProbe 
Inc., San Diego, CA, USA), based on RNA amplification. 
Specimens positive for C. trachomatis were sent to the In-
stitute of Medical Microbiology and Hospital Hygiene of 
Heinrich-Heine University in Duesseldorf, Germany, for L 
genotyping, based on a DNA test (3). Persons who had a 
sample positive for LGV genotype L were defined as LGV-
positive; those positive for other genotypes were defined as 
LGV-negative.
Data on sexual history, behavior, and symptoms were 
collected from participants through a self-administered 
questionnaire. Information on HIV status was self-reported 
or obtained from primary care providers. Results were as-
sessed with 95% CIs, and significance level was set at 0.05. 
The study protocol was approved by the ethical review 
committee of Charité University Hospital, Berlin. Data 
were anonymized, participation was voluntary, and no fi-
nancial incentives were provided.
Of 1,883 MSM recruited at 22 sites in 16 cities, 1,848 
agreed to a pharyngeal swab and 1,754 to a rectal swab. An 
additional 522 samples from either urine or urethral swab 
were obtained. Of those recruited, 166 (8.8%) tested posi-
tive for C. trachomatis by rRNA-based assay (Figure). A 
total of 632 (33.6%) participants were HIV-positive. C. tra-
chomatis prevalence was 10.8% among HIV-positive and 
7.8% among HIV-negative or untested participants (odds 
ratio [OR] 1.42, 95% CI 1.03–1.96).
For logistical reasons, only 154 C. trachomatis–posi-
tive specimens underwent genotyping. Nineteen samples 
were LGV-positive: 17 genotype L2 (16 rectal, 1 pharyn-
geal), 1 genotype L3 (pharyngeal), and 1 genotype L2/L3 
(rectal). For genotyped specimens, LGV prevalence was 
16.5% in rectal specimens and 15.4% in pharyngeal speci-
mens. Overall, LGV prevalence was 1.7% (11/632) among 
HIV-positive and 0.6% (8/1,251) among HIV-negative or 
untested MSM (OR 2.75, 95% CI 1.10–6.88).
Eight (53.3%) of 15 LGV-positive MSM did not report 
recent rectal symptoms (Table 1). HIV-negative MSM more 
often met 1 of their last 3 sexual partners in a bar, pub, or 
club than did HIV-negative MSM (p = 0.03 by t test). How-
ever, we found no substantial differences in sexual practices 
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LGV and no differences between LGV-positive and LGV-
negative MSM (data not shown). 
Overall, 70.2% of C. trachomatis–positive MSM were 
asymptomatic (Table 2). In multivariable logistic regres-
sion analysis, only history of C. trachomatis infection was 
associated with LGV infection. In a model not considering 
history of C. trachomatis infection, the number of male sex 
partners in the previous 6 months was associated with out-
come (OR 1.03, 95% CI 1.01–1.06).
Conclusions
Our study showed rectal and pharyngeal LGV preva-
lences of 16.5% and 15.4%, respectively, among C. tracho-
matis–positive MSM in Germany. Previous reports have 
found that 75% of all LGV cases in MSM were among 
HIV-positive men (1,4); a meta-analysis found HIV preva-
lence of 67%–100% among LGV-positive men (5). In our 
study, 58% of LGV-positive MSM were HIV positive.
In a screening study conducted in London, an 8% 
(247/3,017) prevalence of rectal chlamydia was detected; 
among these infections, 14% were L genotype (6). The co-
infection rate of HIV in men with rectal C. trachomatis 
in that study was 38% (94/247), comparable to the 44% 
in our study. HIV-positive status may be associated with 
having more sexual partners, more frequent unprotected 
receptive anal intercourse, and higher susceptibility to 
LGV infection (4). Because of a relatively small number 
of observations, however, our study lacks the power to de-
tect these differences.
Although the finding was not significant, HIV-nega-
tive MSM who had higher numbers of sexual partners in 
the 6 months before the study were more likely to be LGV-
positive. These men were also more likely to having met 1 
of their previous 3 partners in a bar, pub, or club, settings 
in which explicit HIV serostatus communication is less 
likely to occur (7). This finding indicates that the spread 
of LGV is not confined to sex networks of HIV-positive 
MSM (8).
The prevalence of rectal and pharyngeal C. trachoma-
tis infection we found in MSM in Germany is comparable 
to previously reported rates (9–11). However, because our 
study used a convenience sample of health care–seeking 
men, MSM who have poor health care–seeking behavior 
might be underrepresented, which could mean C. tracho-
matis prevalence is higher than we found. A total of 70% 
of C. trachomatis–positive persons in our study were as-
ymptomatic, similar to the 69% reported from a study in 
the United Kingdom (6).
Our observed proportion of LGV subtypes among C. 
trachomatis–positive persons is in line with published data 
(6). However, the high proportion of asymptomatic cases 
and LGV-positive cases among HIV-negative MSM we 
found is in contrast to other recent findings (6,12), although 
considerable percentages of asymptomatic LGV infections 
have been reported elsewhere (13).
Although it is not licensed for extragenital use, sensi-
tivity and specificity of the RNA-based assay we used is 
high (10,14). Nucleic acid amplification tests may also be 
used for detection of C. trachomatis in pharyngeal and rec-
tal specimens (15). Our initial testing used the APTIMA 
Combo 2 Assay, for which the transport media was adopt-
ed. Because of the lysing effect of the transport medium, 
concentration of pathogens before DNA preparation was 
disqualified and C. trachomatis detection was restricted to 
samples with higher DNA concentrations, leading to a dif-
ferent number of positive samples. To avoid potential bias, 
only specimens that tested positive in both assays were in-
cluded in the analyses.
Another limitation of our study is that not all 166 sam-
ples were sent for further subtyping. The genotype for 12 
specimens remains unknown.
We found no major predictors for LGV infections in 
C. trachomatis–positive MSM. This finding points to 2 op-
tions for control: 1) all MSM diagnosed with C. trachoma-
tis should receive treatment adequate to cure LGV (that is, 
3 weeks of doxycycline rather than 1), or 2) all MSM-de-
rived specimens positive for C. trachomatis should further 
be genotyped to exclude infection with LGV genotypes. 
Physicians should be aware of possible L-genotype infec-
tion in symptomatic or HIV-positive patients and should 
initiate further diagnostic tests. In the absence of commer-
cially available LGV sequencing tests, clinicians should 
Figure.	Flowchart	of	testing	of	1,883	men	who	have	sex	with	men	
for Chlamydia trachomatis (CT) and lymphogranuloma venereum 
(LGV)	 by	 RNA-	 and	 DNA-based	 assays,	 Germany,	 December	





use in-house PCR tests to detect LGV strains. In addition, 
the observed rate of rectal C. trachomatis and LGV infec-
tions in MSM justifies the implementation of a C. tracho-
matis screening policy for MSM in Germany.
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Table	1.	Characteristics	of	MSM	patients	with	LGV,	by	HIV	status,	Germany,	2009–2010* 
Characteristics HIV negative, n = 8 HIV positive, n = 11 p value 
Median age, y (range) 33	(27–55) 41	(31–46) 0.48 
Origin    
 Germany 7 9 1.0† 
 Abroad 1 (United Kingdom) 2	(Turkey,	Colombia)  
Location	of	LGV    
 Rectal 7 10 1.0† 
 Pharyngeal 1 1  
Genotype    
 L2 7 10  
 L2/L3 1 0  
 L3 0 1  
Symptoms n = 8 n = 10  
 None 5 3 0.34† 
 Symptomatic 3 7  
  Anorectal symptoms‡ 1 12  
  Night	sweats 1 0  
Median	no.	male	sex	partners	in	past	6	mo	(range)    
 All partners 11	(3–180) 2.5 (1–1,000) 0.25 
 Unprotected	anal	sex	partners 2 (0–77) 1 (0–80) 1.0 
Meeting place for >1	of	last	3	partners,	% n = 8 n = 8  
 The Internet 63 63 1.0† 
 Bar/pub/club 75 25 0.13† 
 Sauna 0 13 1.0† 
 Sex	party 25 13 1.0† 
 At friends’ homes 25 0 0.47† 
 Other 0 13 1.0† 
CT test ever, yes/no 2/3 7/1 0.22† 
 If yes, when    
  Past	3	mo 1 5  
  Past 12 mo 1 2  
History of CT 2 5 0.32† 
 If yes, when    
  Past month§ 1 3  
  Past 12 mo 0 1  
  >12	mo 0 1  
If	history	of	CT	in	past	month,	location	of	current	LGV    
 Rectal§ 1 3  
If	history	of	CT	in	past	month,	site	of	last	examination    
 Urine 0 2  
 Rectum 1 1  
 Pharynx 1 0  
 Blood 0 2  
 Do not remember 0 2  
Type of last	examination n = 8 n = 8  
 Urine 1 6  
 Urethral swab 1 0  
 Rectal	swab 5 4  
 Pharyngeal swab 5 3  
 Blood 5 6  
 Do not remember 0 3  
HIV test ever, yes/no 7/1 NA  
 If yes, when    
  Past	3	mo 2 NA  
  Past 6 mo 1 NA  
  Past 12 mo 1 NA  
ART,	yes/no NA 7/1  
*Values	are	no.	patients	except	as	indicated.	MSM,	men	who	have	sex	with	men;	LGV,	lymphogranuloma	venereum;	CT,	Chlamydia trachomatis;	NA,	not	
applicable;	ART,	antiretroviral	therapy. 
†By Fisher exact test. 





Norbert Kellermann, Petra Spornraft-Ragaller, Andreas Klein, 
Ruth Hörnle, Karin Rittner, Kathrin Graefe, Gisela Walter, 
Esther Voigt, Vera Pawassarat, Heiko Jessen, Carmen Zed-
lack, Werner Becker, Corinna Becker, Manuela Buttelmann, 
Felix Laue, Marc Grenz, Gaby Knecht, Gert Hartmann, Pe-
ter Wiesel, Heribert Knechten, Petra Panstruga, Albert May-
er, Florian Zinke, and Torben Schultes. We also thank Ra-
mona Scheufele for her assistance with statistical analyses; 
Marion Steinmetz, Eva Schorn, Nadine Moebius, and Meike 
Rosenblatt for their technical help; and Osamah Hamouda for 
his valuable comments.
This work was supported by the research funds of the Rob-
ert Koch-Institute. Test kits for detection of C. trachomatis in-
fection were provided free of charge by the manufacturer.
The authors are aware that the conclusion regarding imple-
mentation of C. trachomatis screening policies will have financial 
impacts for companies producing respective diagnostic tests. How-
ever, neither GenProbe nor any of its employees had any influence 
on the analysis and interpretation of the data or on the conclu-
sions. None of the authors has any shares or other investments in 
companies producing diagnostic tests for C. trachomatis or LGV. 
 
Table	2.	Characteristics	of	MSM	patients	with	CT	infection,	by	LGV	status,	Germany,	2009–2010* 
Characteristic LGV	positive,	n	=	19 LGV	negative,	n	=	95 p value OR	(95%CI) 
Median age, y (range) 37	(27–55) 30	(19–67) 0.004  
Origin n = 16 n = 80   
 Germany, % (no.) 87.5 (14) 80.0 (64) 0.73† 1.75	(0.34–17.33) 
Reported	symptoms n = 15 n = 69   
 None,	%	(no.) 53.3 (8)‡ 73.9	(51) 0.13 2.48 (0.79–7.81) 
Median	no.	male	sex	partners	in	past	6	mo	(range)    
 All partners 9 (1–1,000) 5 (1–150) 0.11  
 Unprotected	anal	sex	partners 1.5 (0–80) 1 (0–150) 0.43  
Meeting place for >1	of	last	3	partners,	% n = 16 n = 82   
 The Internet 62.5 65.9 0.80 0.86 (0.29–2.62) 
 Bar/pub/club 50.0 26.8 0.08† 2.73	(0.91–8.15) 
 Sauna 6.3 13.4 0.68† 0.43	(0.01–3.43) 
 Sex	party 18.8 3.7 0.05† 6.08 (0.71–49.10) 
 Pornography cinema 0 7.3 0.59† 0.60 (0.00–4.47) 
 Cruising 0 4.9 1.0† 0.95 (0.00–8.02) 
 At friends’ homes 12.5 11.0 1.0† 1.16 (0.11–6.52) 
 Other 6.3 7.3 1.0† 0.84 (0.02–7.81) 
Location	of	sexual	contact	with	last	3	
partners, %§ 
15	patients/33	answers 57 patients/144 answers   
 Germany 100.0 95.1 0.33 2.18 (0.29–) 
 Abroad 0 4.9   
HIV status     
 % Positive 57.9 41.1 0.18 1.97	(0.73–5.36) 
 If positive     
  Median time since diagnosis, y (range) 4.5 (2.75–13.67) 2.1 (0–20.25) 0.22  
  HIV therapy, % n = 8 n = 25   
   Combination therapy 87.5 52.0 0.11† 6.46	(0.63–312.96) 
   No	therapy 12.5 48.0   
  Viral	load,	copies/mL,	% n = 8 n = 22   
   Undetectable	or	<1,000 100.0 54.5 0.03† 0.12 (0.00–0.94) 
   >1,000 0 45.5   
History of CT testing and past infections 19 95   
CT test ever, yes/no 9/4 27/26 0.35† 2.17 (0.52–10.73) 
 If yes, when     
  Past	3	mo 6 11   
  Past 6 mo 1 3   
  Past 12 mo 2 5   
History of CT infection  n = 16 n = 82   
 Yes,	%	(no.) 43.8	(7) 12.2 (10) 0.01† 5.60 (1.40–21.24) 
 If yes, when     
  Past month 4¶ 2 0.57† 3.0	(0.26–35.33) 
  >1	mo 2 3   
If history of CT infection in past month, type of current CT infection, no.    
 Anorectal 4 1   
 Urethral 0 1   
*No.	indicates	no.	persons.	MSM,	men	who	have	sex	with	men;	CT,	Chlamydia trachomatis;	LGV,	lymphogranuloma	venereum;	OR,	odds	ratio. 
†Exact logistic regression 
‡3 of these patients were from 1 proctological referral practice 
§Multiple answers possible. 




H.W., F.W., and B.H. work in medical laboratories that also of-
fer C. trachomatis and/or LGV testing on a commercial basis and 
therefore may financially benefit from broadening C. trachomatis 
screening recommendations to MSM; none of them, however, has 
any influence on the decision-making process of health authorities 
in Germany.
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